Natera’s Signatera Data at ASCO GU Shows Promise for Bladder Cancer Preservation — Natera, Inc.

Event summary

Natera presented new data on Signatera’s utility in genitourinary cancers at ASCO GU, including four oral presentations focused on muscle-invasive bladder cancer (MIBC).
INDIBLADE and RETAIN trials showed 73-77% of MIBC patients achieved ctDNA clearance post-therapy, with Signatera-negativity linked to high bladder-intact event-free survival rates.
NIAGARA trial introduced urinary tumor DNA (utDNA) data, demonstrating complementary risk stratification with ctDNA for residual disease detection.
Signatera’s role in guiding adjuvant immunotherapy and bladder preservation strategies was reinforced across multiple studies.

The big picture

Natera’s data at ASCO GU underscores the growing role of molecular residual disease (MRD) testing in personalized oncology. The findings position Signatera as a key tool for optimizing treatment decisions in MIBC, aligning with broader industry trends toward precision medicine and minimally invasive cancer management. The integration of utDNA and ctDNA data represents a significant step forward in risk stratification, potentially setting a new standard for perioperative care.

What we're watching

Clinical Validation: Whether Signatera’s strong correlations with outcomes will accelerate regulatory approvals and clinical adoption.
Market Expansion: The pace at which Natera can expand Signatera’s utility across other genitourinary malignancies beyond bladder cancer.
Competitive Positioning: How Natera differentiates Signatera in a growing field of MRD detection tools, particularly in bladder preservation strategies.